Public company, workplace, funding, and market signals
Karius is a clinical metagenomics company that uses genomic sequencing and AI to detect microbial cell-free DNA for infectious-disease diagnosis, with blood- and BAL-based laboratory-developed tests designed to help clinicians reach faster, more actionable treatment decisions.
Primary product
Karius Spectrum (blood-based metagenomic infectious-disease test)
Founded
2014
Headquarters
Redwood City, California, United States
Team size
100-150
Work style
Hybrid
Industry
Biotechnology Research
Sub-industry
Clinical metagenomics / infectious disease diagnostics
Offices
Business model
Leadership
Chief Executive Officer
Chief Scientific Officer
Chief Technology and Business Officer
Publicly described culture emphasizes integrity and truthfulness, open communication, curiosity, creativity, courage, sanity and balance, teamwork, humility, and a patient-first, high-urgency operating style.
Work style
Hybrid
Compensation
Public recruiting materials say total compensation includes salary or wages, bonuses, and equity; no public salary bands were found.
Benefits
Pricing
Per-test clinical laboratory fee / laboratory-developed test pricing; public materials have cited a historical Karius Test list price of about $2,000.
Differentiators
Technology
Estimated revenue
$10M-$20M
9 jobs at Karius
Nov 2018 · Oxford Finance LLC
Aug 2017 · Data Collective (DCVC) and Lightspeed Venture Partners
Sep 2014 · DCVC
Chief Medical Officer
Chief Legal Officer and Corporate Secretary
Bill Quirk
Chief Financial Officer
Chief Commercial Officer
Chief People Officer
Founders
Co-founder; President & Chief Product Officer
Stephen Quake, PhD
Scientific co-founder
Investors
Customers
Competitors